Domain licenses Parkinson's drug candidates to Merck Serono spinoff

01/24/2013 | Genetic Engineering & Biotechnology News

Merck Serono spinoff Prexton Therapeutics was given an exclusive option by Domain Therapeutics to advance through clinical development stage its metabotropic glutamate receptor 4-positive allosteric modulator drug candidates against Parkinson's disease. The chemical series emerged from joint work by Domain and Merck Serono.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT